10:33 AM
 | 
Aug 28, 2017
 |  BC Extra  |  Preclinical News

Teams identify GFRAL as target for obesity

In three separate papers published in Nature Medicine on Monday, researchers at Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO), Eli Lilly and Co. (NYSE:LLY) and the Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) each identified GDNF family receptor alpha like (GFRAL) as a...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >